Femasys, Inc. (FEMY)

Femasys' stock price has significantly declined over the past year. Key events include the Q3 2025 earnings release, a Nasdaq minimum bid price requirement extension, European commercial expansion, FemBloc MDSAP certification, FemaSeed CPT code approval, initiation of the FINALE pivotal trial for FemBloc, Q4 2025 earnings release and corporate update, appointment of a Chief Operating Officer, Israeli market entry, launch of FemaSeed® Complete, and Q1 2026 financial results. Despite positive announcements, the stock has traded at low levels, indicating market skepticism.

Specific information regarding the demand seasonality for Femasys, Inc.'s products and services was not explicitly found in the search results. Therefore, there is no direct information available to describe the demand seasonality for Femasys' products and services.

Femasys, Inc. is a biomedical company focused on transforming women's healthcare through minimally invasive, in-office therapeutic and diagnostic solutions for reproductive health. The company operates in the Healthcare sector, specifically in the Medical Instruments & Supplies industry, providing accessible and cost-effective options for infertility treatment and non-surgical permanent birth control. Key products include FemaSeed, FemVue, FemBloc, FemSperm, FemChec, FemCerv, and FemCath.

Femasys is a U.S. manufacturer with global regulatory approvals. Its products are commercially available in the United States and select international markets, including Europe, the UK, Canada, and Israel. The company is actively expanding its international commercial footprint through partnerships.

Femasys generally maintains a positive brand reputation due to its focus on innovation, patient safety, and addressing unmet needs. Regulatory approvals, clinical milestones, positive analyst sentiment, and the company's mission contribute positively to its reputation. However, the declining stock price could indirectly affect investor confidence and public perception.

Institutional investors hold a significant portion of Femasys Inc.'s stock, accounting for 65.27% of the shares. Major institutional owners include Dauntless Investment Group, LLC, Vanguard Group Inc, and BlackRock, Inc. Individual/insider owners include Edward R. Uzialko, Kathy Leesepsick, John Dyett, and John Q. Adams Jr.